In 2007, BGI came to Shenzhen and established BGI-Research. BGI-Research follows the academic tradition and innovative spirit of BGI, with a focus on novel scientific research with a good application value. The Institute is dedicated to the research of genomes, tumors, brain science, reproductive health and animal and plant molecular breeding. Based on major scientific projects on human health, animals, plants and microorganisms, the Institute conducts in-depth scientific research and core technology development at DNA level, RNA level, DNA and histone modification level, protein level, network/system biology level, tuple level, population and evolutionary omics levels, metabolomics levels, synthetic biology levels and the single cell level.
Established in 2011, BGI College's mission is to “improve disciplines, industry and talents via real world projects. BGI College relies on BGI's powerful research platforms, major scientific research projects and industrial development chain to carry out an innovative genomics curriculum . BGI college is dedicated to international open education and training innovative talents that are needed for scientific research and industrial development in the life sciences.
China National GeneBank (CNGB) is one of the key science infrastructures in Shenzhen, approved and funded by the Chinese government. CNGB is committed to supporting public welfare, life science research, innovation and industry development, through effective bioresource conservation, digitalization and utilization.
China National GeneBank (CNGB) is owned by the government and operated independently by BGI-Research under the guidance and supervision of State High-Tech Industrial Innovation Center, Shenzhen (HIIC).
CNGB is a public, non-profit, open, and enabling platform. It facilitates advanced genomics R&D and technology transfer to industrial application, including precision medicine, agriculture, marine sciences and microbial application, towards its mission of making genetic resources “Owned by All, Completed by All and Shared by All”.
GigaScience aims to revolutionize publishing by promoting reproducibility of analyses and data dissemination, organization, understanding, and use. As an open access and open-data journal, GigaScience publishes ALL research objects (data, software tools and workflows) from 'big data' studies across the entire spectrum of life and biomedical sciences. These resources are managed using the FAIR Principles for scientific data management and stewardship that state that research data should be Findable, Accessible, Interoperable and Reusable.To achieve its goals, the journal has a novel publication format: one that links standard manuscript publication with an extensive database that hosts all associated data and provides data analysis tools and cloud-computing resources. GigaDB provides a direct link between the published manuscript and the relevant supporting data. GigaScience have also built GigaGalaxy, a Galaxy-based data analysis platform to host computational methods and workflows, maximizing use of the data, tools and workflows in our papers in a more accessible and reproducible environment.
On July 14, 2017, BGI Genomics was officially listed and became the 2001st listed company of the Shenzhen Stock Exchange. BGI Genomics is one of the world's leading genomics test and research service providers, providing genomics test and research services for medical institutions, research institutions, enterprises and institutions through genetic testing and other means. BGI Genomics is committed to helping and accelerating scientific innovation, strengthening the prevention and control of cancer and other genetic diseases, improving diagnostic tools for the rapid diagnosis of infectious disease and helping the development of precision medicine. Relying on cutting edge bioinformatics pipelines, advanced R&D, high-performance proprietary NGS sequencing technology, mass spectrometers,and underpinned by a decade of commercial experience, BGI Genomics provides its customers with expert and affordable clinical molecular diagnostic solutions and NGS services for research.
MGI is committed to enabling effective and affordable healthcare solutions for all. MGI produces sequencing devices, equipment, consumables and reagents to support life science research, medicine and healthcare.
MGI's multi-omics platforms include genetic sequencing, mass spectrometry and medical imaging. Its mission is to develop and promote advanced life science tools for future healthcare.
FGI is committed to providing world-leading high-accuracy forensic DNA testing to benefit the society. FGI innovates forensic application through integrating industry, education, and research. It has one of the first third-party forensic centers approved by Ministry of Justice of China.